Novel antipsychotics: Comparison of weight gain liabilities

Journal of Clinical Psychiatry

Volumn 60, Issue 6, 1999, Pages 358-363

  Wirshing, Donna A ^a,b,d   Wirshing, William C ^a,b   Kysar, Lisa ^b   Berisford, M Andrew ^a   Goldstein, Danielle ^a   Pashdag, Joanna ^c   Mintz, Jim ^a   Marder, Stephen R ^a,b  

^a VA Gtr Los Angeles Hlthcare S ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PEPPERDINE UNIVERSITY   (United States)

^d Gtr Los Angeles VA Hlthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; SERTINDOLE; THIORIDAZINE;

ADULT; ARTICLE; BODY WEIGHT; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0033037295     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0602     Document Type: Article

References (49)

1. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988;153:214-217
2. Bernstein JG. Psychotropic drug induced weight gain: mechanism and management. Clin Neuropharmacol 1988;11:S194-S206
3. Rockwell WJ, Ellinwood EH, Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J 1983; 76:1407-1412
4. Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989;82:611-617
5. Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affect Disord 1984;7:133-138
6. Pi-Sunyer FX. Medical hazards of obesity. Ann Int Med 1993;119: 655-660
7. Luo SQ, Li ET. Effects of repeated administration of serotonergic agonists on diet selection and body weight in rats. Pharmacol Biochem Behav 1991;38:495-500
8. Samanin R, Garattini S. The pharmacology of serotonergic drugs affecting appetite. In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, vol 8. New York, NY: Raven Press; 1990:163-192
9. Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977;1:15-42
10. Goodall E, Oxtoby C, Richards R, et al. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208-213
11. Silverstone T, Goodall E. Serotoninergic mechanisms in human feeding: the pharmacological evidence. Appetite 1986;7:85-97
12. Fletcher PJ. Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline, and ritanserin. Psychopharmacology (Berl) 1988;96:237-242
13. 2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Psychopharmacology (Berl) 1992;109:444-448
14. Leysen JE, Gommeren W, Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane JM, Moller HJ, Awouters F, eds. Serotonin in Antipsychotic Treatment. New York, NY: Marcel Dekker; 1996:51-75
15. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT-2c serotonin receptors. Nature 1995;374:542-546
16. Garattini S, Mennini T, Samain R. Reduction of food intake by manipulation of central serotonin: current experimental results. Br J Psychiatry 1989;155(suppl 8):41-51
17. Walsh AE, Smith KA, Oldman AD, et al. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Berl) 1994;116: 120-122
18. Fjalland B, Boeck V. Neuroleptic blockade of the effect of various neurotransmitter substances. Acta Pharmacol Toxicol (Copenh) 1978;42: 206-211
19. Schotte A, Janssen PF, Megens AA, et al. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202
20. Wilson JD, Hillas JL. Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis. Clin Allergy 1983;13:131-140
21. Knight A. Astemizole: a new, non-sedating antihistamine for hayfever. J Otolaryngol 1985;14:85-88
22. 1 receptor antagonist: effect on allergic rhinoconjunctivitis, on antigen and histamine induced skin response and relationship to serum levels. Br J Clin Pharmacol 1984;18:1-8
23. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry 1994;55(5, suppl):22-28
24. 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 1992;89:61-69
25. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-551
26. Jann MW. Clozapine. Pharmacotherapy 1991;11:179-195
27. Meltzer HY. Mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287
28. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2: 281-293
29. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72
30. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149: 689-690
31. Cohen S, Chiles J, MacNaughten A. Weight gain associated with clozapine. Am J Psychiatry 1990;147:503-504
32. Mertens C. Long-term treatment of chronic schizophrenic patients with risperidone. In: Kane JM, ed. Risperidone: Major Progress in Antipsychotic Treatment. Oxford, England: Oxford Clinical Communications; 1991: 44-48
33. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(5, suppl):29-35
34. 2 pKi values. J Pharmacol Exp Ther 1989;251:238-246
35. Weidley EF, Setler PE, Rush JA. The serotonin blocking properties of antipsychotic drugs. Pharmacologist 1980;22:279
36. Fink H, Morgenstern R, Oelssner W. Clozapine: a serotonin antagonist? Pharmacol Biochem Behav 1984;20:513-517
37. Meert TF, de Haes P, Janssen PA. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology (Berl) 1989;97:206-212
38. Harmon L, Berisford A, Ames D, et al. Weight gain associated with effects of atypical antipsychotic agents [abstract]. Neuropsychopharmacology 1994;10(3S, part 2):139S
39. SAS Institute Inc. SAS ProcGLM (Procedure General Linear Model). Cary, NC: SAS Institute; 1992
40. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
41. Amdisen A. Drug-produced obesity: experiences chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964;11:182-189
42. Johnson DAW, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979;59:525-528
43. Kalucy RS. Drug-induced weight gain. Drugs 1980;19:268-278
44. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(9, suppl B):157-160
45. Mason JB, Rosenberg IH. Protein-energy malnutrition. In: Isselbacher KJ, Martin JB, Braunwald AB, et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:440-446
46. Ames D, Marder SR, Wirshing WC, et al. Ongoing research in the drug treatment of schizophrenia. In: Kane JM, Moller HJ, Awouters F, eds. Serotonergic Mechanisms in Antipsychotic Treatment. New York, NY: Marcel Dekker; 1996:13-30
47. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15:24S-29S
48. Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav 1990;36:837-841
49. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783